- Home
- PSBD vs FHTX Comparison
PSBD vs FHTX Comparison
Compare PSBD & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PSBD | FHTX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.7M | 323.4M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PSBD | FHTX |
|---|---|---|
| Price | $11.12 | $4.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $12.33 | $11.50 |
| AVG Volume (30 Days) | 82.0K | ★ 110.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 15.02% | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ 1.66 | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | $8.89 |
| Revenue Next Year | N/A | $20.13 |
| P/E Ratio | $6.58 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $9.34 | $3.27 |
| 52 Week High | $14.96 | $6.95 |
Technical Indicators
Market Signals| Indicator | PSBD | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 42.62 |
| Support Level | $10.24 | $4.44 |
| Resistance Level | $11.14 | $5.82 |
| Average True Range (ATR) | 0.36 | 0.27 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 84.62 | 13.54 |
Price Performance
Historical ComparisonAbout PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.